Houston research team invents cost-saving innovation for automated drug dosing

groundbreaking tech

Rice University synthetic biologists created a device to demonstrate a new method that could slash the costs of creating wearable monitors for precision, automated drug dosing of chemotherapies and other drugs. Photo by Jeff Fitlow/Rice University

A team of Rice University researchers has built a technology that uses a $20 blood-glucose sensor to potentially automate dosing of practically any drug.

In a paper recently published in Nature, researchers in Caroline Ajo-Franklin’s lab shared that they were able to modify the inexpensive piece of equipment to detect afimoxifene, an estrogen inhibitor that is naturally produced by a patient’s body after taking the chemotherapy drug tamoxifen.

“The dream is to have technology similar to what’s available today for monitoring and treating variations in blood glucose, and have that be true for basically any drug,” said Ajo-Franklin, a bioscientist, cancer researcher and director of the Rice Synthetic Biology Institute in a press release from Rice University. “Millions of people use blood-glucose monitors every day. If we can use that same basic technology to monitor other drugs and biomarkers, we could move away from the one-size-fits-all dosing regimes that we’re stuck with today.”

The lead author of the study was postdoctoral research associate Rong Cai. She and the team tested more than 400 modified versions of the electron-releasing proteins (what creates the current that glucose monitors detect) until they found a version that reacted with afimoxifene. Essentially, they built an afimoxifene sensor that could reliably detect the presence of the drug.

According to Ajo-Franklin, her team is currently at work testing ways to identify drugs other than afimoxifene.

In a press release, Cai said, “The glucometer is the part that’s so well-developed. While our target is different, it’s just a matter of engineering and changing the protein on the inside. On the outside, everything will still be the same. You can still do the test with a strip or on your arm.”

Better still, she went on to say that because the signal is electrical, it can be sent to a phone or computer to be read and stored.

“That’s the part, that marriage between electricity and biology, that is very attractive,” Cai said.

Rice University synthetic biologists (from right to left) Caroline Ajo-Franklin, Chiagoziem Ngwadom and Rong Cai worked with Rice engineer Rafael Verduzco (left) to create and demonstrate a method of universalizing blood-glucose detection technology as a way of rapidly and inexpensively creating sensors that can monitor the dosing of chemotherapies and other drugs in real time. Photo by Jeff Fitlow/Rice University

This week's roundup of Houston innovators includes Tatiana Fofanova of Koda Health, Rafael Verduzco of Rice University, and Sujata “Su” Bajaj and Dakisha Allen of Yuvo Health. Photos courtesy

4 Houston innovators to know this week

who's who

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to four local innovators across industries — from digital health to research — recently making headlines in Houston innovation.

Tatiana Fofanova, co-founder and CEO of Koda Health

Tatiana Fofanova, co-founder and CEO of Koda, joined the Houston Innovators Podcast to discuss her company's growth. Image via LinkedIn

It's Tatiana Fofanova's goal to have Koda Health's platform — a B2B Enterprise SaaS solution that guides patients through the process of proactive healthcare planning and document authentication — active in all 50 states by the end of the first quarter of 2023. She's already halfway there.

The tech platform allows for patients and their providers to get on the same page for their care. Fofanova describes the platform as similar to TurboTax — users answer a series of questions and the program provides a care plan then shared with the patient's doctors. This greatly simplifies — and democratizes — the process for patients and providers both.

"The standard of care for advanced care planning has traditionally been left to patients to do on their own — with estate planning attorney or through a direct-to-consumer solution," Fofanova says on this week's episode of the Houston Innovators Podcast. Read more.

Rafael Verduzco, associate chair and a professor of chemical and biomolecular engineering and of materials science and nanoengineering at Rice University

Rafael Verduzco is leading the research and development. Photo by Jeff Fitlow/Rice University

A team of researchers from Rice University have received a $2 million grant to develop a unique technology that speeds up the analysis of wastewater for viruses from hours to seconds. The team is based out of Rice’s George R. Brown School of Engineering and led by Rafael Verduzco, associate chair and a professor of chemical and biomolecular engineering and of materials science and nanoengineering. The four-year grant from the National Science Foundation will support the development of the technology, which includes wastewater-testing bioelectric sensors that deliver immediate notice of presence of viruses like SARS-CoV-2, which causes COVID-19, according to a news release from Rice.

“Monitoring wastewater for COVID has been pretty effective as a way to get an idea of where we are as a population,” says Verduzco in the release. “But the way it’s done is you have to sample it, you have to do a PCR test and there’s a delay. Our selling point was to get real-time, continuous monitoring to see just how much of this virus is in the wastewater.” Read more.

Sujata “Su” Bajaj as CTO and Dakisha Allen as head of product of Yuvo Health

Two Houstonians have been named to the executive board of a New York startup. Photos courtesy of Yuvo Health

ANew York City-based, tech-enabled health administrative and managed care solution has announced the latest addition to its C-suite — including two executives based in Houston.

Yuvo Health, which provides community health centers a tech platform for managing care, announced the appointment of Sujata “Su” Bajaj as CTO and Dakisha Allen as head of product. Additionally, the startup named New York-based Anthony Thompson as head of development and Ishaan Jalan as chief of staff.

“It is with tremendous pride and excitement that we announce the growth of our leadership team, especially as it is less than six months since our last corporate expansion,” says Cesar Herrera, CEO and co-founder of Yuvo Health. Read more.

A team out of the engineering school at Rice University has created a technology for real-time wastewater monitoring. Photo via rice.edu

Houston research team snags $2M grant for virus sensing tech

money moves

A team of researchers from Rice University have received a $2 million grant to develop a unique technology that speeds up the analysis of wastewater for viruses from hours to seconds.

The team is based out of Rice’s George R. Brown School of Engineering and led by Rafael Verduzco, associate chair and a professor of chemical and biomolecular engineering and of materials science and nanoengineering. The four-year grant from the National Science Foundation will support the development of the technology, which includes wastewater-testing bioelectric sensors that deliver immediate notice of presence of viruses like SARS-CoV-2, which causes COVID-19, according to a news release from Rice.

The research project — with its partners at the Houston Health Department — have already developed water testing procedures and have analyzed samples from locations around the city. The current process includes taking samples and transferring them to Rice for analysis, but the new technology would be able to monitor systems onsite and instantly. The parties involved with this work are also collaborating with the Centers for Disease Control and Prevention Center of Excellence for wastewater epidemiology that was announced in August.

The grant's co-principal investigators include Jonathan Silberg, the Stewart Memorial Professor of BioSciences and director of the Systems, Synthetic and Physical Biology Ph.D. program, and Caroline Ajo-Franklin, a professor of biosciences. Co-investigators also include Lauren Stadler, an assistant professor of civil and environmental engineering, and Kirstin Matthews, a fellow at the Baker Institute for Public Policy.

“These are engineered microbes we’re putting into wastewater, and even though they’re encapsulated, we want to know if there are concerns from health authorities and the general population,” Verduzco said. “Kirstin’s role is to look at the policy side, and also gauge public reaction and educate people about what it means when we talk about engineered bacteria.”

Rafael Verduzco is leading the research and development. Photo by Jeff Fitlow/Rice University

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

3 Houston incubators and accelerators fueling the growth of local startups

Meet the finalists

It takes a village to launch a business. That's where Houston's network of incubators and accelerators can step in, providing the resources, mentorship and community needed to push a fledgling company forward.

As part of our 2026 Houston Innovation Awards, the Incubator/Accelerator of the Year category honors a local organization that is championing and fueling the growth of Houston startups.

Three incubators and accelerators have been named finalists for the 2026 award. They support startups ranging from hard-tech companies to food and youth concepts.

Read more about these organizations below. The 2026 winners will be announced on InnovationMap.com in mid-November.

Activate

Hard tech incubator Activate supports scientists in "the outset of their entrepreneurial journey." The Houston hub was introduced in 2024, and joins others in Boston, New York, and Berkley, California—where Activate is headquartered. It named its third Houston cohort this summer.

The two-year program graduated its first class of Houston fellows in 2026 and saw its first alumni IPO from Houston-based Fervo Energy, which previously participated in a Berkley cohort. Nationally, it has supported 346 fellows and 276 companies since 2015. Those companies have raised more than $6 billion in follow-on funding, according to Activate. In Houston, it has supported Houston startups like Solidec, FlowCellutions and Orbital Arc. Activate Houston is led by managing director Jeremy Pitts, who co-founded Greentown Labs in Boston. It is based out of the Ion.

Impact Hub Houston

Impact Hub Houston supports early-stage ventures at various stages of development through innovative programs that address pressing societal issues. The nonprofit organization supports social impact startups through mentorship, connections and training opportunities.

There are more than 110 Impact Hubs globally with members spanning 72 countries. Launched in 2018, Impact Hub Houston says its membership tripled by the beginning of 2026. This year brought major milestones for the community, including the launch of its Ideas to Impact Accelerator, which supported 11 founders across the health, education, food systems, civic technology and workforce development sectors. It also received funding from more than 20 international Impact Hubs to develop SYNC, a collaboration platform that 25 Impact Hubs across five continents have committed to pilot. The organization has worked with local startups including Myoviva Health, The Change Lab and INNERVERSE Inc.

MarMo Innovation

Galveston-based business incubator MarMo Innovation is focused on removing barriers to entrepreneurship. It aims to provide affordable space, education, mentorship, market access, connections and real-world opportunities that help entrepreneurs move from idea to launch to sustainable growth. The "industry-agnostic" incubator was founded in 2022 and is led by Executive Director Erica Delgadillo.

This year, the organization moved from primarily serving as a coworking and community space into a more comprehensive entrepreneurial incubator by expanding its MarMo Market, MarMo Market Jr. and Lunch LineUp programs. A major focus for MarMo is food entrepreneurship. It is developing an Incubator Kitchen, which MarMo says will support programs like its Cottage to Commercial Bootcamp and Food Biz 101. The organization also expanded its board this year and says it is diversifying its revenue through memberships, events, markets, equipment and space rentals, sponsorships, grants and new entrepreneurial programming.

Baylor College of Medicine launches VC fund to invest in biotech startups

fresh funding

Houston’s Baylor College of Medicine just unveiled a new venture capital fund that backs early-stage biotech startups—and it’s already made its first investment.

BCM Legacy Fund I, funded by philanthropies, invested an undisclosed amount in Houston biotech startup Nemea Therapeutics. Nemea, a spinout of the Baylor College of Medicine and Germany’s Lead Discovery Center, is developing an oral drug to treat metastatic triple-negative breast cancer that no longer responds to currently available therapies.

This type of aggressive cancer spreads from the breast to other areas of the body, such as the bones, liver, lungs or brain. Roughly 38,000 to 57,000 Americans are diagnosed each year with metastatic triple-negative breast cancer. One study showed about half of patients survive past the one-year mark following diagnosis and about one-third survive two years.

“Baylor College of Medicine’s laboratories produce discoveries with the potential to change patients’ lives, and too many of them stall where academic funding ends and private investment has not yet begun,” Dr. Jakub Tolar, president, CEO and executive dean of the Baylor College of Medicine, said in a press release. “The BCM Legacy Fund fills that gap, giving our scientists a path to advance their discoveries to patients.”

The National Institutes of Health awards more than $36 billion per year for biomedical research in the U.S., Baylor said. But some biomedical discoveries “never leave the starting line because they don’t yet fit the economics of venture capital,” the college said.

“The forefront of a new model”

The BCM Legacy Fund aggregates philanthropic capital from private foundations and donor-advised funds. It then invests in startups so they can move beyond that starting line and into later-stage investment rounds. The Greater Houston Community Foundation is the fund’s philanthropic partner.

“It’s exciting to be on the forefront of a new model for philanthropic capital,” said Houston entrepreneur and investor Burton Hanson, managing partner of the fund.

“Not only do we hope to solve a real problem by advancing these therapies to the patients who need them most, but we also hope this model will inspire others in the city and beyond toward philanthropic creativity and a posture of ‘I sacrifice; we win.’”

The fund expects to invest in about 15 early-stage startups over a five-year span. Baylor declined to divulge the amount of money in the fund and the size of the investment in Nemea.

Nemea’s “world-class chemistry”

Hanson oversees the Baylor fund alongside Chicago investor Steve Lehmann, who led the University of Chicago’s Innovation Fund.

Lehmann said Nemea, the fund’s first portfolio company, “has world-class chemistry, Baylor biology, and patients with no good options. Our job is to fund the experiments that carry it to the next handoff, so that industry and later-stage investors can take it from there.”

Based at Houston’s massive Texas Medical Center, Nemea plans to start clinical trials next year in collaboration with Baylor’s Lester and Sue Smith Breast Center.

Nemea previously received $9 million from the Lead Discovery Center and a $1.6 million grant from Baylor. Last year, the startup said it was seeking $25 million to $30 million in seed and Series A funding.

Debra McCoy of Houston, a former managing director at BlackRock and former partner at Bain & Co., and Paul Thomas, co-founder and CEO of Spring-based benefits manager Luscinia Health, sit on the Baylor fund’s governing board. Dr. Paul Klotman, former president, CEO and executive dean of Baylor, is a senior strategic adviser.

How does the fund find investment targets?

The Baylor Legacy Fund relies on two tools to help unearth early-stage biotech startups:

High-resolution “innovation maps” of research institutions. These maps surface hidden clusters of innovation, identify rising-star researchers and tie pockets of “innovation supply” at Baylor to areas of “innovation demand” in biotech.
AI-enhanced due diligence. AI agents assist with due diligence of early-stage biotech startups. The fund says the platform “distills the frameworks we’ve developed over a decade of teaching and investing into a flexible … diligence environment.”

MD Anderson unveils $3.4B expansion with two new Houston cancer care facilities

major expansion

The cutting edge of cancer-fighting technology and science is getting even sharper after MD Anderson announced last week that it will open two new facilities in the Texas Medical Center within the next five years. Inspiration Tower and Prism will expand MD Anderson’s annual patient load in the TMC to 250,000 annually and will incorporate a variety of new techniques.

The $3.4 billion project will add 2 million square feet to MD Anderson's TMC footprint, bringing its total campus size to 22 million square feet by 2032. Located at the corner of Fannin Street and Holcombe Boulevard, the cancer center says the two new facilities will serve as its new "front door" to the TMC.

“Every detail of these buildings, from the technology to the treatment rooms, was designed around our patients who will receive their care in them and our employees who will work in them. The facilities will serve as a physical representation of hope for the patients and their families who will walk through the doors,” Dr. Jeffrey E. Lee, president ad interim of UT MD Anderson, said in a news release. “Inspiration Tower and Prism are the future of cancer care, and we are grateful for the longstanding support and guidance we’ve received from the UT System Board of Regents to bring these projects to life. These facilities are part of the most impactful capital expansion in UT MD Anderson’s history.”

Prism is especially exciting as it will represent fully half of the linear accelerator treatment in the TMC. Linear accelerator is a radiation treatment that uses magnetically charged fields to deliver targeted external radiation therapy, like shooting cancer with a rail gun. The treatment is safer and has fewer side effects than older radiation treatments.

In addition, Prism will contain 12 MRI machines, four CT scanners, two PET-CT units, 18 radiation vaults and seven radiation simulators. Patient comfort has also been put at a premium with multiple gardens and roof overlooks.

“Every patient we treat deserves an environment that reflects the excellence of the care they receive at UT MD Anderson,” Chris McKee, executive vice president and chief strategy officer at UT MD Anderson, added in the release. “Our new facilities will be innovative, agile, adaptable and beautiful, and they will allow us to care for more patients, more effectively – in an environment that enhances healing and well-being. We are building for our future and for every patient who will be counting on us.”

Prism is slated to open in 2030.

Inspiration Tower will have 25 floors of surgical, diagnostic, and treatment services. At 1.4 million square feet, it’s currently expected to be the largest cancer-specific treatment facility in the United States. The tower will be divided into units for specific types of cancer, making it easy to integrate the advancing research being done all over Houston.

Like Prism, Inspiration Tower is specifically designed to offer comfort and reassurance, with more garden space, terraces, and beautiful scenery to ease patient distress. It is expected to open in 2032.

View All Listings

INNOVATIONMAP EMAILS ARE AWESOME